猴痘疫苗储备投资案的流行病学建模与成本效益分析
为支持Gavi投资猴痘疫苗储备的决策,研究构建确定性分区模型模拟两种疫苗接种策略与两种响应速度,并纳入蒙特卡洛成本效益分析。结果显示快速响应(20例即干预)使用单剂策略的净收益更高,且100万剂储备的效益成本比最高。
要点
- 快速响应(20例即干预)比100例后响应净收益更高。
- 单剂策略在快速响应下每避免一个DALY的成本更低。
- 100万剂储备规模的效益成本比最高。
核心结论
- 快速响应并使用单剂疫苗接种策略相比两剂策略具有更高的效益成本比。
- 100万剂的猴痘疫苗储备规模具有最高的效益成本比。
研究设计与样本
- 开发了包含疫苗干预的猴痘传播确定性分区模型,模拟两种响应速度(20例或100例报告时干预)与两种接种策略(一剂或两剂)在高风险人群和病例接触者中的效果。
- 模型结果被纳入对不同储备规模的蒙特卡洛成本效益分析。
主要发现
- 在20例报告时快速响应并使用单剂策略,每避免一个DALY的总成本比100例后响应低18%至53%。
- 储备100万剂疫苗的效益成本比最高。
关键数值与推荐
- 快速响应定义为在报告20例病例时进行干预。
- 单剂策略在20例报告时响应的每DALY避免成本比100例报告时响应低18%至53%。
- 100万剂储备规模的效益成本比最高。
临床怎么用
- 在猴痘疫情早期(报告20例时)即启动单剂疫苗接种响应可最大化净健康收益和成本效益。
- 储备100万剂猴痘疫苗可作为实现高效益成本比的参考规模。
- 降低疫苗价格和采用剂量节约策略可进一步提高猴痘疫苗储备的成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In response to ongoing mpox outbreaks, Gavi, the Vaccine Alliance, was considering funding the establishment of an mpox vaccine stockpile. To support their decision making, Gavi commissioned the Center for Outbreak Response Innovation at the Johns Hopkins Bloomberg School of Public Health to estimate the optimal size, impact, health benefits, and monetised net benefits of different mpox vaccine stockpile sizes for an effective global stockpile to support outbreak containment and prevention of widespread mpox transmission. We aimed to quantify the potential impact of vaccination on future mpox outbreaks to inform Gavi's decision making for investing in an effective mpox vaccine stockpile. METHODS: A deterministic compartmental model of mpox transmission with vaccine interventions was developed, including intervening rapidly-at 20 cases reported-versus at 100 cases reported. The model was used to assess potential vaccine-based mitigation strategies for mpox outbreaks in Gavi-eligible countries by simulating mpox transmission and control dynamics, given two vaccination strategies (one dose and two doses) compared with no intervention in high-risk groups and contacts of cases, across four distinct subpopulations: (1) children younger than 5 years, (2) men who have sex with men, (3) female sex workers, and (4) the remaining general population. The findings from this model were incorporated into a Monte Carlo cost-benefit analysis of different stockpile sizes. FINDINGS: Rapid response (ie, intervening at 20 cases reported) using a single-dose vaccination strategy provided the greatest benefits relative to costs compared with a two-dose strategy. Using a one-dose strategy, expected net benefits were estimated to be over US$81 million to $220 million higher when responding to outbreaks rapidly than when responding after 100 cases. Furthermore, the total cost per disability-adjusted life-year (DALY) averted with rapid response using a one-dose vaccine strategy responding at 20 cases was 18% to 53% lower than a one-dose strategy introduced at 100 cases. A stockpile of 1 000 000 doses had the highest ratio of benefits to costs. INTERPRETATION: A stockpile calibrated to attain a high ratio of benefits to costs can be effective in controlling outbreaks and reducing overall negative health impacts. The cost-effectiveness of mpox vaccine stockpiles could be further maximised with reduced vaccine pricing and dose-sparing strategies. FUNDING: Gavi, the Vaccine Alliance.
引用
- Mitcham D, Bruns R, Goodtree H, et al. Informing an mpox stockpile investment case: epidemiological modelling and cost-benefit analysis. Lancet Glob Health. 2026. PMID: 42854705. doi:10.1016/j.langlo.2026.104069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。